Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia

Postprandial Glycemia Clinical Trial

Official title:

Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02940080
• Other study ID #: Siniset perunat 2
• Status: Completed
• Phase: N/A
• Start date: October 2016
• Est. completion date: December 31, 2021

Study information

• Verified date: March 2022
• Source: University of Turku
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, single-blind cross-over clinical nutrition trial will be conducted. The effects of yellow-fleshed potatoes and yellow-fleshed potatoes supplemented with anthocyanins extracted from purple-fleshed potatoes on healthy men's postprandial glycemia and insulinemia will be compared. Additionally, the postprandial metabolism and metabolites, and the appearance and metabolism of the flavonoids and their metabolites is studied in plasma, urine and feces.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Age 18-45

• Male

• No regular medication

• No participation in a drug trial or blood donation within 2 months

• Non-smoker

• Signs informed consent

• Body mass index 18.5-27 kg/m2

• Fasting plasma cholesterol < 5.5 mmol/l

• Fasting plasma triacylglycerols < 2.6 mmol/l

• Fasting plasma glucose 4-6 mmol/l

• blood pressure <140/80 mmHg

• hemoglobin>130 g/l

• Fasting plasma alanine amino transferase (ALAT) <60 U/l (normal liver function)

• Fasting plasma thyroid-stimulating hormone (TSH) 0.4 - 4.5 mU/l (normal thyroid function)

• Fasting plasma creatinine <118 µmol/l (normal kidney function)

Exclusion Criteria:

• Regular smoking

• Alcohol abuse

• Regular medication

Related Conditions & MeSH terms

• Postprandial Glycemia

Intervention

Other:
• Dietary

Locations

Country	Name	City	State
Finland	Department of Biochemistry, University of Turku	Turku

Sponsors (1)

Lead Sponsor	Collaborator
University of Turku

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Plasma glucose concentration		0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Primary	Plasma insulin concentration		0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Secondary	Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in plasma (NMR and (U)HPLC-MS/MS measurements)		0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Secondary	Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in urine (NMR and (U)HPLC-MS/MS measurements)		Before meal, and 0-4h, 4-8h, 8-16h, 16-24 h
Secondary	Concentrations and quality of metabolites and flavonoid color compounds and their metabolites in feces (NMR and (U)HPLC-MS/MS measurements)		before and after meal
Secondary	Area under the glucose concentration curve (AUC)		0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min
Secondary	Area under the insulin concentration curve (AUC)		0min, 20min, 40min, 60min, 90min, 120min, 180min, 240min